Homologous recombination deficiency (HRD) and platinum sensitivity are prospective biomarkers for predicting the response to PARP inhibitors in ovarian cancers. The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.